---
title: "Nanomaterial Strategies to Reprogram Macrophages for Inflammation and Tumor Therapy"
id: "pubmed-42900219"
canonical_url: "https://medichelpline.com/clinical-feed/pubmed-42900219"
content_type: "clinical_feed_article"
specialty: "Oncology"
source_name: "PubMed / NCBI"
source_url: "https://pubmed.ncbi.nlm.nih.gov/42900219/"
doi: "10.1021/acsabm.6c01937"
published_at: "2026-11-02T00:00:00.000Z"
evidence_level: "Journal Article"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Nanomaterial Strategies to Reprogram Macrophages for Inflammation and Tumor Therapy
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/pubmed-42900219
- **Specialty:** [Oncology](https://medichelpline.com/clinical-feed/oncology.md)
- **Primary Source:** PubMed / NCBI
- **Source URL:** [Original Journal Publication](https://pubmed.ncbi.nlm.nih.gov/42900219/)
- **DOI:** [10.1021/acsabm.6c01937](https://doi.org/10.1021%2Facsabm.6c01937)
- **Published At:** 2026-11-02T00:00:00.000Z
- **Evidence Rating:** Journal Article
## Executive GIST (TL;DR)
- Macrophages act in opposing roles across disease states: protective during acute inflammation but driving chronic inflammation and promoting tumor growth when polarized to immunosuppressive states. - The review compares nanomaterial design strategies targeting disease-site macrophages in inflammatory disorders and cancer, focusing on delivery of immunomodulatory agents. - Approaches described include inhibition of the **CCL2-CCR2** chemokine axis, selective macrophage elimination via apoptosis, and metabolic reprogramming to alter macrophage phenotype. - Authors examined biomimetic and apoptotic cell-inspired nanoparticles that exploit natural macrophage clearance pathways to encourage M2 polarization in inflammatory settings. - For tumors, activation strategies using **TLR** and **STING** agonists delivered by nanocarriers aim to reverse immunosuppression and stimulate antitumor responses. - The review details how nanoparticle surface chemistry, composition, and targeting ligands influence differential therapeutic outcomes while retaining shared principles such as EPR-mediated accumulation. - Next-generation nanoparticle platforms in clinical trials for cancer and inflammatory diseases are noted, though specific agents and trial identifiers are not reported in the abstract. - Translational barriers are emphasized: nanoparticle-related immunotoxicity, macrophage heterogeneity, and manufacturing reproducibility limit clinical application and require targeted solutions.
## Clinical Analysis & Structured Key Points
Clipboard, Search History, and several other advanced features are temporarily unavailable. [ Skip to main page content ](https://pubmed.ncbi.nlm.nih.gov/42900219/#article-details) ### NIH Websites Are Changing * [Get the Latest Updates and FAQs on the transition](https://www.nih.gov/web-modernization) * Per [Executive Order 14434](https://www.whitehouse.gov/presidential-actions/2026/09/inaugurating-the-era-of-super-intelligence/), federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition. ![U.S. flag](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/favicons/favicon-57.png) An official website of the United States government Here's how you know ![Dot gov](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-dot-gov.svg) **The .gov means it’s official.** Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site. ![Https](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-https.svg) **The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. [ ![NIH NLM Logo](https://cdn.ncbi.nlm.nih.gov/coreutils/nwds/img/logos/AgencyLogo.svg) ](https://www.ncbi.nlm.nih.gov/) [Log in](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42900219%2F) Show account info Close #### Account Logged in as: **username** * [Dashboard](https://www.ncbi.nlm.nih.gov/myncbi/) * [Publications](https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/) * [Account settings](https://www.ncbi.nlm.nih.gov/account/settings/) * [Log out](https://www.ncbi.nlm.nih.gov/account/signout/?back_url=https%3A//pubmed.ncbi.nlm.nih.gov/42900219/) [Access keys](https://www.ncbi.nlm.nih.gov/guide/browsers/#ncbi_accesskeys) [NCBI Homepage](https://www.ncbi.nlm.nih.gov) [MyNCBI Homepage](https://pubmed.ncbi.nlm.nih.gov/myncbi/) [Main Content](https://pubmed.ncbi.nlm.nih.gov/42900219/#maincontent) [Main Navigation](https://pubmed.ncbi.nlm.nih.gov/42900219/) [ ![pubmed logo](https://cdn.ncbi.nlm.nih.gov/pubmed/a447896c-976f-490b-b86b-2668b65114a8/core/images/pubmed-logo-blue.svg) ](https://pubmed.ncbi.nlm.nih.gov/) [ ](https://pubmed.ncbi.nlm.nih.gov/42900219/ "Show search bar") Search: [](https://pubmed.ncbi.nlm.nih.gov/42900219/ "Clear search input")Search [Advanced](https://pubmed.ncbi.nlm.nih.gov/advanced/) [ Clipboard ](https://pubmed.ncbi.nlm.nih.gov/clipboard/) [ User Guide ](https://pubmed.ncbi.nlm.nih.gov/help/) Save Email Send to * [ Clipboard ](https://pubmed.ncbi.nlm.nih.gov/42900219/) * [My Bibliography](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42900219%2F%23open-bibliography-panel) * [Collections](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42900219%2F%23open-collections-panel) * [Citation manager](https://pubmed.ncbi.nlm.nih.gov/42900219/) Display options Display options Format Abstract PubMed PMID ## Save citation to file Format: Summary (text) PubMed PMID Abstract (text) CSV Create file Cancel ## Email citation Email address has not been verified. Go to [ My NCBI account settings ](https://account.ncbi.nlm.nih.gov/settings/) to confirm your email and then refresh this page. To: Subject: Body: Format: Summary Summary (text) Abstract Abstract (text) MeSH and other data Send email Cancel ### Add to Collections * Create a new collection * Add to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42900219/) Add Cancel ### Add to My Bibliography * My Bibliography Unable to load your delegates due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42900219/) Add Cancel ## Your saved search Name of saved search: Search terms: [Test search terms](https://pubmed.ncbi.nlm.nih.gov/42900219/) Would you like email updates of new search results? Saved Search Alert Radio Buttons * Yes * No Email: ([change](https://www.ncbi.nlm.nih.gov/account/settings/)) Frequency: Monthly Weekly Daily Which day? The first Sunday The first Monday The first Tuesday The first Wednesday The first Thursday The first Friday The first Saturday The first day The first weekday Which day? Sunday Monday Tuesday Wednesday Thursday Friday Saturday Report format: Summary Summary (text) Abstract Abstract (text) PubMed Send at most: 1 item 5 items 10 items 20 items 50 items 100 items 200 items Send even when there aren't any new results Optional text in email: Save Cancel ## Create a file for external citation management software Create file Cancel ## Your RSS Feed Name of RSS Feed: Number of items displayed: 5 10 15 20 50 100 Create RSS Cancel RSS Link Copy ### Full text links [![Silverchair Information Systems full text link](https://cdn.ncbi.nlm.nih.gov/corehtml/query/egifs/https:--pubs.acs.org-ImageLibrary-acs_fulltext.png) Silverchair Information Systems ](https://pubs.acs.org/aabmcb/article-lookup/doi/10.1021/acsabm.6c01937 "See full text options at Silverchair Information Systems") [ Full text links ](https://pubmed.ncbi.nlm.nih.gov/42900219/) ### Actions Cite Collections Add to Collections * Create a new collection * Add to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42900219/) Add Cancel Permalink Permalink Copy Display options Display options Format Abstract PubMed PMID ### Experimental Resource Linked Discoveries ### Page navigation * [ Title & authors ](https://pubmed.ncbi.nlm.nih.gov/42900219/#heading) * [ Abstract ](https://pubmed.ncbi.nlm.nih.gov/42900219/#abstract) * [ Publication types ](https://pubmed.ncbi.nlm.nih.gov/42900219/#publication-types) * [ MeSH terms ](https://pubmed.ncbi.nlm.nih.gov/42900219/#mesh-terms) * [ Substances ](https://pubmed.ncbi.nlm.nih.gov/42900219/#substances) * [Related information](https://pubmed.ncbi.nlm.nih.gov/42900219/#related-links) * [ LinkOut - more resources ](https://pubmed.ncbi.nlm.nih.gov/42900219/#linkout) Title & authors Abstract Publication types MeSH terms Substances Related information LinkOut - more resources Review ACS Appl Bio Mater Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22ACS+Appl+Bio+Mater%22%5Bjour%5D&sort=date&sort_order=desc) * [ Search in NLM Catalog ](https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22ACS+Appl+Bio+Mater%22%5BTitle+Abbreviation%5D) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42900219/) . 2026 Nov 2;9(21):10063-10089. doi: 10.1021/acsabm.6c01937. # Nanomaterial Design for Macrophage Reprogramming: Emerging Strategies and Mechanistic Insights for Inflammation and Tumor Therapy [Nitish Giri](https://pubmed.ncbi.nlm.nih.gov/?term=Giri+N&cauthor_id=42900219)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42900219/#full-view-affiliation-1 "Department of Chemistry, School of Advanced Sciences, Vellore Institute of Technology, Vellore632014, Tamil Nadu, India."), [Atanu Chakraborty](https://pubmed.ncbi.nlm.nih.gov/?term=Chakraborty+A&cauthor_id=42900219)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42900219/#full-view-affiliation-1 "Department of Chemistry, School of Advanced Sciences, Vellore Institute of Technology, Vellore632014, Tamil Nadu, India.") Affiliations Expand ### Affiliation * 1 Department of Chemistry, School of Advanced Sciences, Vellore Institute of Technology, Vellore632014, Tamil Nadu, India. * PMID: **42900219** * DOI: [ 10.1021/acsabm.6c01937 ](https://doi.org/10.1021/acsabm.6c01937) Item in Clipboard Review # Nanomaterial Design for Macrophage Reprogramming: Emerging Strategies and Mechanistic Insights for Inflammation and Tumor Therapy Nitish Giri et al. ACS Appl Bio Mater. 2026. Show details Display options Display options Format Abstract PubMed PMID ACS Appl Bio Mater Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22ACS+Appl+Bio+Mater%22%5Bjour%5D&sort=date&sort_order=desc) * [ Search in NLM Catalog ](https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22ACS+Appl+Bio+Mater%22%5BTitle+Abbreviation%5D) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42900219/) . 2026 Nov 2;9(21):10063-10089. doi: 10.1021/acsabm.6c01937. ### Authors [Nitish Giri](https://pubmed.ncbi.nlm.nih.gov/?term=Giri+N&cauthor_id=42900219)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42900219/#short-view-affiliation-1 "Department of Chemistry, School of Advanced Sciences, Vellore Institute of Technology, Vellore632014, Tamil Nadu, India."), [Atanu Chakraborty](https://pubmed.ncbi.nlm.nih.gov/?term=Chakraborty+A&cauthor_id=42900219)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42900219/#short-view-affiliation-1 "Department of Chemistry, School of Advanced Sciences, Vellore Institute of Technology, Vellore632014, Tamil Nadu, India.") ### Affiliation * 1 Department of Chemistry, School of Advanced Sciences, Vellore Institute of Technology, Vellore632014, Tamil Nadu, India. * PMID: **42900219** * DOI: [ 10.1021/acsabm.6c01937 ](https://doi.org/10.1021/acsabm.6c01937) Item in Clipboard Full text links Cite Display options Display options Format Abstract PubMed PMID Linked Discoveries ## Abstract Macrophages play a paradoxical role in inflammation and tumor. They can protect the host during acute inflammation but act as the main driver for the chronic inflammation which is a common characteristic of several diseases including rheumatoid arthritis, atherosclerosis, type 2 diabetes, inflammatory bowel disease, and neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease. In the tumor microenvironment, macrophages switch their phenotype to the immunosuppressive M2 state that promotes tumor growth, angiogenesis, and metastasis. Emerging nanomaterial platforms are trying to offer transformative solutions by enabling the precise delivery of immunomodulatory drugs directly to disease-site macrophages. This review will provide comprehensive comparative analysis of these emerging nanomaterial designs strategies across two disease paradigms: inflammatory diseases and tumor. The discussion will focus on various strategies which include inhibiting chemokine axis (CCL2-CCR2 axis), selective elimination of macrophages through apoptosis, metabolic reprogramming, biomimetic and apoptotic cell-inspired nanoparticles leveraging natural macrophage clearance pathways to promote M2 polarization in inflammation, and the activation of tumor-associated macrophages via TLR and STING agonist. We highlight the role of nanoparticle surface chemistry, composition, and targeting ligands in achieving the two opposite therapeutic outcomes of these two diseases while maintaining some common design principles including EPR-mediated accumulation at the disease sites and biomimetic modifications. We also mentioned novel next-generation nanoparticle-based platforms that are currently in clinical trials for the treatment of tumor and inflammatory diseases. Finally, we discuss the barriers that limit the clinical translational potential of broad nanoparticles, with particular emphasis on nanoparticle-related immunotoxicity, macrophage heterogeneity, and manufacturing reproducibility of the nanoparticles. **Keywords:** biomimetic nanoparticles; immunomodulatory drug delivery; inflammation; macrophage reprogramming; nanomaterials; tumor therapy. © 2026 American Chemical Society. [PubMed Disclaimer](https://pubmed.ncbi.nlm.nih.gov/disclaimer/) ## Publication types * Review Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Review%22%5Bpt%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Review) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42900219/) ## MeSH terms * Animals Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Animals%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Animals) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42900219/) * Antineoplastic Agents* / chemistry Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Antineoplastic+Agents%2Fchemistry%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Antineoplastic+Agents) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42900219/) * Antineoplastic Agents* / pharmacology Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Antineoplastic+Agents%2Fpharmacology%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Antineoplastic+Agents) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42900219/) * Biocompatible Materials* / chemistry Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Biocompatible+Materials%2Fchemistry%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Biocompatible+Materials) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42900219/) * Biocompatible Materials* / pharmacology Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Biocompatible+Materials%2Fpharmacology%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Biocompatible+Materials) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42900219/) * Humans Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Humans%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Humans) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42900219/) * Inflammation* / drug therapy Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Inflammation%2Fdrug+therapy%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Inflammation) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42900219/) * Inflammation* / pathology Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Inflammation%2Fpathology%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Inflammation) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42900219/) * Macrophages* / drug effects Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Macrophages%2Fdrug+effects%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Macrophages) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42900219/) * Macrophages* / metabolism Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Macrophages%2Fmetabolism%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Macrophages) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42900219/) * Nanostructures* / chemistry Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Nanostructures%2Fchemistry%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Nanostructures) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42900219/) * Neoplasms* / drug therapy Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Neoplasms%2Fdrug+therapy%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Neoplasms) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42900219/) * Neoplasms* / pathology Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Neoplasms%2Fpathology%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Neoplasms) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42900219/) ## Substances * Biocompatible Materials Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Biocompatible+Materials%22%5Bnm%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=%22Biocompatible+Materials%22) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42900219/) * Antineoplastic Agents Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Antineoplastic+Agents%22%5Bnm%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=%22Antineoplastic+Agents%22) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42900219/) ## Related information * [ MedGen ](https://www.ncbi.nlm.nih.gov/medgen?linkname=pubmed_medgen&from_uid=42900219 "Related information in MedGen") ## LinkOut - more resources * ### Full Text Sources * [ Silverchair Information Systems ](https://pubs.acs.org/aabmcb/article-lookup/doi/10.1021/acsabm.6c01937) * ### Research Materials * [ NCI CPTC Antibody Characterization Program ](https://antibodies.cancer.gov/detail/CPTC-STING1-1) **Full text links** [x] [![Silverchair Information Systems full text link](https://cdn.ncbi.nlm.nih.gov/corehtml/query/egifs/https:--pubs.acs.org-ImageLibrary-acs_fulltext.png) Silverchair Information Systems ](https://pubs.acs.org/aabmcb/article-lookup/doi/10.1021/acsabm.6c01937 "See full text options at Silverchair Information Systems") [x] Cite Copy Download .nbib .nbib Format: AMA APA MLA NLM **Send To** * [Clipboard](https://pubmed.ncbi.nlm.nih.gov/42900219/) * [Email](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42900219%2F%23open-email-panel) * [Save](https://pubmed.ncbi.nlm.nih.gov/42900219/) * [My Bibliography](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42900219%2F%23open-bibliography-panel) * [Collections](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42900219%2F%23open-collections-panel) * [Citation Manager](https://pubmed.ncbi.nlm.nih.gov/42900219/) [x] NCBI Literature Resources [MeSH](https://www.ncbi.nlm.nih.gov/mesh/) [PMC](https://www.ncbi.nlm.nih.gov/pmc/) [Bookshelf](https://www.ncbi.nlm.nih.gov/books) [Disclaimer](https://pubmed.ncbi.nlm.nih.gov/disclaimer/) The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited. Follow NCBI [ Twitter ](https://twitter.com/ncbi) [ Facebook ](https://www.facebook.com/ncbi.nlm) [ LinkedIn ](https://www.linkedin.com/company/ncbinlm) [ GitHub ](https://github.com/ncbi) [ ](https://ncbiinsights.ncbi.nlm.nih.gov/) [Connect with NLM](https://www.nlm.nih.gov/socialmedia/index.html) * [ Twitter ](https://twitter.com/NLM_NIH) * [ SM-Facebook ](https://www.facebook.com/nationallibraryofmedicine) * [ SM-Youtube ](https://www.youtube.com/user/NLMNIH) National Library of Medicine [8600 Rockville Pike Bethesda, MD 20894](https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/@38.9959508,-77.101021,17z/data=!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb:0x19156f88b27635b8!8m2!3d38.9959508!4d-77.0988323) [Web Policies](https://www.nlm.nih.gov/web_policies.html) [FOIA](https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office) [HHS Vulnerability Disclosure](https://www.hhs.gov/vulnerability-disclosure-policy/index.html) [Help](https://support.nlm.nih.gov/?pagename=pubmed%3Apubm
## Related Clinical Research

- [Vitamin B5 derivative linked to reduced psoriasis plaques and inflammation in small trial](https://medichelpline.com/clinical-feed/medical-news-today-0-vitamin-b5-derivative-may-reduce-psoriasis-plaques-and-inflammation-small-trial.md)
- [Retatrutide: A New Approach for Easing Knee Osteoarthritis Pain](https://medichelpline.com/clinical-feed/medical-news-today-0-new-weight-loss-drug-eases-knee-osteoarthritis-pain-in-major-trials.md)
- [Bupropion Hydrochloride for Improving Recovery in Acute Ischaemic Stroke: BASE Trial Protocol](https://medichelpline.com/clinical-feed/bmj-open-4-protocol-for-base-a-multicentre-double-blind-randomised-controlled-trial-of.md)
- [Climate change worsens health for people with chronic illness](https://medichelpline.com/clinical-feed/stat-news-1-opinion-climate-change-is-making-people-with-chronic-illness-even-sicker.md)
- [Nuclear-transport–targeting peptides (SN50 family) as broad anti-inflammatory agents](https://medichelpline.com/clinical-feed/frontiers-in-immunology-17-targeting-the-nuclear-gateway-a-new-class-of-cell-penetrating-peptides-for.md)

## Navigation
- [← Back to Oncology Feed](https://medichelpline.com/clinical-feed/oncology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.